Polydatin as a Multifunctional Anticancer Agent: Cellular Mechanisms, Therapeutic Potential and Future Clinical Perspectives
Cell Biology International · 2026
DOI: 10.1002/cbin.70145 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cell Biology International, 2026. Verfasst von Putri Cahaya Situmorang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biology, Faculty of Mathematics and Natural Sciences, Universitas Sumatera Utara, Medan, North Sumatra, Indonesia. Hauptthemen laut MEDLINE: Glucosides, Stilbenes, Neoplasms, Antineoplastic Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 132 Literaturangaben.
Abstract (Originalsprache)
Cancer remains one of the leading causes of death worldwide, with conventional treatments often facing limitations such as toxicity, drug resistance, and reduced effectiveness over time. Polydatin (PD), a natural glycosylated derivative of resveratrol, has emerged as a promising therapeutic compound due to its ability to induce apoptosis, regulate the cell cycle, modulate oxidative stress, and inhibit angiogenesis. Additionally, PD plays a key role in shaping the tumor microenvironment and enhancing immune responses, making it a strong candidate for use alongside chemotherapy and radiotherapy. This review examines PD's pharmacological potential, highlighting its anticancer mechanisms, therapeutic combinations, and clinical relevance. A systematic literature search was conducted using PubMed, Scopus and Web of Science to analyze preclinical and clinical studies published between 2010 and 2024. Findings suggest that PD enhances chemotherapy efficacy, increases tumor sensitivity to radiotherapy, and reduces drug resistance by targeting critical signaling pathways, including phosphoinositide 3‐kinase/protein kinase B (PI3K/Akt), nuclear factor kappa‐light‐chain‐enhancer of activated B cells (NF‐κB) and mitogen‐activated protein kinase (MAPK). Beyond cancer treatment, PD has demonstrated cardioprotective, neuroprotective, and hepatoprotective properties, further supporting its clinical potential. Despite encouraging preclinical evidence, clinical studies on PD remain limited, emphasizing the need for further investigations into its pharmacokinetics, bioavailability, and safety. Moving forward, research should focus on improving drug delivery systems, conducting rigorous clinical trials, and exploring PD's role in precision medicine to maximize its therapeutic impact in oncology and beyond.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biology, Faculty of Mathematics and Natural Sciences, Universitas Sumatera Utara, Medan, North Sumatra, Indonesia.
- Department of Obstetrics and Gynecology, Faculty of Medicine, Universitas HKBP Nommensen, Medan, North Sumatra, Indonesia.
- Department of Pharmacology, Faculty of Pharmacy, Universitas Sumatera Utara, Medan, North Sumatra, Indonesia.
- Universidad Espíritu Santo, Samborondón, Ecuador.
- Department of Medicine, College of Medicine, Korea University, Seoul, South Korea.
- Department of Clinical Pharmacy, University of Medicine and Pharmacy of Craiova, Craiova, Romania.
ORCID-Profile: Rony Abdi Syahputra, Javad Sharifi-Rad, Daniela Calina
Zitieren
APA
Situmorang, P. C., Rumahorbo, C. G. P., Simanjuntak, L. J., Syahputra, R. A., Sharifi-Rad, J., & Calina, D. (2026). Polydatin as a Multifunctional Anticancer Agent: Cellular Mechanisms, Therapeutic Potential and Future Clinical Perspectives. Cell Biology International. https://doi.org/10.1002/cbin.70145
Vancouver
Situmorang PC, Rumahorbo CGP, Simanjuntak LJ, Syahputra RA, Sharifi-Rad J, Calina D. Polydatin as a Multifunctional Anticancer Agent: Cellular Mechanisms, Therapeutic Potential and Future Clinical Perspectives. Cell Biology International. 2026. doi:10.1002/cbin.70145
BibTeX
@article{Situmorang2026,
author = {Situmorang, Putri Cahaya and Rumahorbo, Cheryl Grace Pratiwi and Simanjuntak, Leo Jumadi and Syahputra, Rony Abdi and Sharifi-Rad, Javad and Calina, Daniela},
title = {Polydatin as a Multifunctional Anticancer Agent: Cellular Mechanisms, Therapeutic Potential and Future Clinical Perspectives},
journal = {Cell Biology International},
year = {2026},
doi = {10.1002/cbin.70145}
}
EUVIMED